- Home
- CCIF vs PYXS Comparison
CCIF vs PYXS Comparison
Compare CCIF & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCIF | PYXS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 82.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCIF | PYXS |
|---|---|---|
| Price | $3.35 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 105.5K | ★ 372.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.01 | $0.97 |
| 52 Week High | $6.85 | $5.55 |
Technical Indicators
Market Signals| Indicator | CCIF | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 53.27 | 56.72 |
| Support Level | $3.22 | $1.28 |
| Resistance Level | $3.46 | $2.17 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 58.62 | 44.59 |
Price Performance
Historical ComparisonAbout CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.